-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Acquired Hemophilia A Diagnosis and Management

Program: Education Program
Hematology Disease Topics & Pathways:
Bleeding and Clotting, Diseases, Therapies
Saturday, December 9, 2023: 9:30 AM-10:45 AM
Room 28 A-D (San Diego Convention Center)

Description:
This session will provide an update on the management of acquired hemophilia A (AHA). The first part will review laboratory diagnosis and monitoring of the disease until stable remission. The second part will discuss immunosuppressive regimens, including newer regimens with reduced toxicity. The last part will explore the role of emicizumab in the management of AHA in light of upcoming clinical trial results.

Chair:
Andreas Tiede, MD, Hannover Medical School
Disclosures:
Tiede: Bayer: Honoraria, Research Funding; Biomain: Honoraria; Biotest: Honoraria, Research Funding; Chugai/Roche: Honoraria, Research Funding; CSL Behring: Honoraria; Novo Nordisk: Honoraria, Research Funding; Octapharma: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding; SOBI: Honoraria, Research Funding; Takeda: Honoraria, Research Funding.
This session will provide an update on the management of acquired hemophilia A (AHA). The first part will review laboratory diagnosis and monitoring of the disease until stable remission. The second part will discuss immunosuppressive regimens, including newer regimens with reduced toxicity. The last part will explore the role of emicizumab in the management of AHA in light of upcoming clinical trial results.
Diagnosis and Laboratory Monitoring of Acquired Haemophilia A

Sean Platton, MSc CSci FIBMS

Royal London Hospital Haemophilia Centre, Barts Health NHS Trust, London, ENG, United Kingdom
Immunotherapy of Acquired Hemophilia A

Andreas Tiede, MD

Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
The Role of Emicizumab in Acquired Hemophilia A

Rebecca Kruse-Jarres, MD, MPH

University of Washington, Seattle, WA
See more of: Education Program
<< Previous Session | Next Session >>